Quant Biomarkers

1. Executive Summary (Confidence: High)

Quant Biomarkers is at the forefront of the "longevity diagnostics" movement, bridging the gap between advanced analytical chemistry and digital health. Headquartered in Basel and founded in 2021, the company targets Chronic Kidney Disease (CKD) and metabolic syndrome through two flagship products: RenoRisk Detect and RenoPredict. By utilizing top-down mass spectrometry to identify specific isoforms of Human Serum Albumin (HSA), the company achieves higher sensitivity than conventional tests, enabling the detection of organ damage long before clinical symptoms appear. Their strategic value lies in a multi-stakeholder business model that serves clinicians, pharmaceutical R&D, and the insurance industry, offering a clear ROI through early intervention and the reduction of healthcare costs associated with aging.